No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

In experiments conducted in a biosafety level 3 facility, the researchers studied ferrets that had antibodies to seasonal flu ...

Moderna already has a bird flu vaccine in very early-stage testing that uses the same mRNA technology that allowed rapid development and rollout of vaccines to protect against COVID-19.

The Phase 1/2 study evaluated a two-dose regimen of Moderna’s investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response.

In May, the U.S. government terminated contracts worth $766 million awarded to the company for the late-stage development of an mRNA-based bird flu vaccine, as well as the right to purchase this ...

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for ...

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for ...